A neuroglial cooperativity is required for the potentiation by 2-chloroadenosine of the muscarinic-sensitive phospholipase C in the striatum.
In rat striatal slices, 2-chloroadenosine, which had no direct effect on inositol phosphate formation, potentiated in a dose-dependent manner the accumulation of inositol phosphates induced either by carbamylcholine (10(-3) M) or by noradrenaline (10(-4) M). Experiments made on pure populations of striatal neurons or striatal glial cells in primary culture from mouse embryos indicated that 2-chloroadenosine potentiated the noradrenaline-elicited phosphoinositide breakdown in striatal glial cultures but did not modify the responses evoked either by noradrenaline or by carbamylcholine in striatal neuronal cultures. However, 2-chloroadenosine enhanced both the carbamylcholine and the noradrenaline-induced accumulation of inositol phosphates in neuroglial cocultures just as it did in rat striatal slices. The potentiation by 2-chloroadenosine of the carbamylcholine response, which is neuron specific, involved a cooperative effect between neurons and glial cells and, as shown by additional experiments, required a brief contact only between the 2 types of cells. The potentiating effect of 2-chloroadenosine was blocked completely by a nonselective A1, A2 adenosine antagonist isobutylmethylxanthine either on rat striatal slices or on mouse embryonic cocultures (noradrenaline and carbamylcholine responses) or on mouse embryonic glial cultures (noradrenaline response). These data indicate the involvement of an extracellular membrane-bound adenosine receptor, possibly of the A1 subtype since N6-cyclohexyladenosine, an A1 adenosine receptor agonist, was more efficient than 5'-N-ethylcarboxamide-adenosine, a rather selective A2 adenosine receptor agonist. We propose that 2-chloroadenosine acts through an adenosine receptor located on glial cells and induces the synthesis of a substance that improves the coupling between carbamylcholine or noradrenaline and phospholipase C located in glial cells or neurons.
el-Etr
M
M
College de France, INSERM U 114, Chaire de Neuropharmacologie, Paris.
Cordier
J
J
Glowinski
J
J
Premont
J
J
D015762:2-Chloroadenosine; D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000243:Adenosine Deaminase / Q000494:pharmacology; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D002478:Cells, Cultured; D003342:Corpus Striatum / Q000166:cytology / Q000201:enzymology* / Q000378:metabolism; D003584:Cytological Techniques; D004357:Drug Synergism; D066298:In Vitro Techniques; D007295:Inositol Phosphates / Q000378:metabolism; D009116:Muscarine / Q000494:pharmacology*; D009457:Neuroglia / Q000502:physiology*; D009474:Neurons / Q000378:metabolism; D009638:Norepinephrine / Q000494:pharmacology; D011983:Receptors, Purinergic / Q000502:physiology; D010738:Type C Phospholipases / Q000378:metabolism*
D007295:Inositol Phosphates; D011983:Receptors, Purinergic; D015762:2-Chloroadenosine; D009116:Muscarine; D002217:Carbachol; D010738:Type C Phospholipases; D000243:Adenosine Deaminase; D000241:Adenosine; D009638:Norepinephrine